3-环丙基吡唑-4-甲醛 | 154927-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-环丙基吡唑-4-甲醛
• 英文名称: 3-cyclopropyl-1H-pyrazole-4-carbaldehyde
• 英文别名: 5-cyclopropyl-1H-pyrazole-4-carbaldehyde
• CAS: 154927-00-1
• 化学式: C₇H₈N₂O
• 分子量: 136.153
• InChiKey: AJISPHYBQBLYBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,4-二氯嘧啶 、 3-环丙基吡唑-4-甲醛 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 、 1-(2-chloropyrimidin-4-yl)-3-cyclopropyl-1H-pyrazole-4-carbaldehyde
  参考文献：
  名称：

  Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors

  摘要：

  A series of pyrazolylpyrimidine scaffold based Syk inhibitors were synthesized and evaluated for their biological activities and selectivity. Lead optimization efforts provided compounds with potent Syk inhibition in both enzymatic and TNF-a release assay. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.011

文献信息

• [EN] SUBSTITUTED NITROGEN CONTAINING COMPOUNDS<br/>[FR] COMPOSÉS CONTENANT DE L'AZOTE SUBSTITUÉ
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018222795A1

  公开（公告）日：2018-12-06

  Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

  揭示了以下式（I）的化合物或其盐，式（II）其中R1是：或；每个W独立地是NR1b或O；Z是键或CHR1d；以及R1、R2、Rd、R3a、R3b、L1、B、V、Y和n在此处被定义。还揭示了将这些化合物用作ROMK抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗心血管疾病方面是有用的。
• Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10723723B2

  公开（公告）日：2020-07-28

  Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

  公开了式(I)化合物或其盐，其中R1是(II)或(III)；每个W独立地是NR1b或O；Z是键或CHR1d；R1、R2、Rd、R3、L1、L2、R1a、R1b、R1c和n在此定义。还公开了使用此类化合物作为 ROMK 抑制剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗心血管疾病。
• SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3535258A1

  公开（公告）日：2019-09-11
• SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3535258B1

  公开（公告）日：2021-11-24
• SUBSTITUTED NITROGEN CONTAINING COMPOUNDS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3630752A1

  公开（公告）日：2020-04-08